References

1. Saisho Y (2014) Obesity, type 2 diabetes and beta cell failure: An Asian perspective. J Mol Genet Med S1: 008. View
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Betacell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110. View
3. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10 Suppl 4: 32-42. View
4. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, et al. (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45: 85-96. View
5. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258. View
6. Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, et al. (2011) Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 58: 315-322. View
7. Saisho Y, Kou K, Tanaka K, Abe T, Shimada A, et al. (2013) Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetol 50: 987-988. View
8. Tsai EB, Sherry NA, Palmer JP, Herold KC (2006) The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49: 261-270. View
9. Torn C (2003) C-peptide and autoimmune markers in diabetes. Clin Lab 49: 1-10. View
10. Fujiwara D, Takahashi K, Suzuki T, Shii M, Nakashima Y, et al. (2013) Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy. J Diabetes Invest 4: 618-625. View
11. Lee EY, Hwang S, Lee SH, Lee Y-h, Choi AR, et al. (2014) Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes. J Diabetes Invest. View
12. Iwao T, Sakai K, Sata M (2013) Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 27: 87-91. View
13. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36: 195-201. View
14. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-1603. View
15. Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and betacell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456-1467. View
16. Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51 Suppl 1: S212-220. View
17. Okuno Y, Komada H, Sakaguchi K, Nakamura T, Hashimoto N, et al. (2013) Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes. Metabolism 62: 1470-1476. View
18. Oram RA, Rawlingson A, Shields BM, Bingham C, Besser RE, et al. (2013) Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open 3: e003193. View
19. Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, et al. (2014) The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med 31: 403-411. View
20. Saisho Y, Kou K, Tanaka K, Abe T, Shimada A, et al. (2013) Association between beta cell function and future glycemic control in patients with type 2 diabetes. Endocr J 60: 517-523. View
21. Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, et al. (2011) Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int 2: 146-153. View
22. Tanaka C, Saisho Y, Tanaka K, Kou K, Tanaka M, et al. (2014) Factors associated with glycemic variability in Japanese patients with diabetes. Diabetol Int 5: 36-42. View
23. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, et al. (2011) Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 60: 1552-1560. View
24. TODAY Study Group (2013) Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care 36: 1749-1757. View